Genomic Health, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (22)

Latest Posts

About This Stock More About This Stock
A Peek Into Latest 13-F Filing: Top Hedge Fund Stocks
Article By: Sweta Killa
Friday, May 18, 2018 9:08 PM EDT
Investors are mulling over the top bets of big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller, following the first-quarter release of 13F Forms.
In this article: EA, AAPL, ADBE, AMZN, MSFT, NFLX, FB, GOOGL, TWX, UNH, ANTM, CVS, ESRX, GRBK, TUSK, GHDX, ZGNX, RTRX, PCRX, PTCT, CORI, SBBP
Read
Rayno Tools And Molecular Diagnostics: Looking For Value
Article By: Rod Raynovich
Thursday, November 5, 2015 7:30 PM EDT
Life Science stocks took a big hit over the past summer and many have not fully recovered. The important metric to watch is sales growth because many of the smaller cap companies are still lagging in earnings growth so the PE tells you very little.
In this article: ALR, CPHD, GHDX, ILMN, LMNX, QDEL, ABAX, HOLX, NEOG, PACB, QGEN, FMI
Read
Rayno Dx And Tools: 2015 Q1 Mid Quarter Update-FMI, CSII, HOLX, ALR
Article By: Rod Raynovich
Thursday, February 19, 2015 4:41 PM EDT
Major ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%.
In this article: FMI, CSII, HOLX, ALR, FBT, IBB, XBI, CPHD, ILMN, ABAX, QGEN, TMO, EXAS, GHDX, NEOG, NSTG, PACB, QDEL, SQNM, VRML
Read
JPMorgan Healthcare Conference Notes #4: Next Gen Sequencing
Article By: Rod Raynovich
Monday, January 19, 2015 7:11 PM EDT
Seminar: Harnessing the Power of Next Gen Sequencing: The View from Industry 1/12/15
In this article: FMI, GHDX, ILMN, PACB, SQNM, TMO
Read
CYTR Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin; GHDX Predicts Outcomes In Prostate Cancer Patients
Article By: BioMedReports
Thursday, December 4, 2014 3:29 AM EDT
CYTR announced that its clinical trials for aldoxorubicin have been placed on partial clinical hold. GHDX announced results from two studies of the Oncotype DX® prostate cancer test.
In this article: GHDX, CYTR
Read

PARTNER HEADLINES

Latest Tweets for $GHDX

No tweets yet!